Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Phase IIa trial begins of MediciNova's ibudilast

Nov. 22, 2012

FDA assigns action date for Orexo's Zubsolv NDA

Nov. 19, 2012

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Nov. 9, 2012

ADX-71441 shows promise in preclinical model of alcohol binge drinking

Oct. 30, 2012

DepoVax found to enhance effect of investigational cocaine vaccine

Oct. 26, 2012

Nabi Biopharmaceuticals reports results from phase II NicVAX vaccine study

Oct. 18, 2012

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Sep. 28, 2012

University of Pittsburg presents new radioprotectants

Sep. 17, 2012

Pivotal pharmacokinetic study of BEMA-buprenorphine/naloxone meets objectives

Sep. 14, 2012

Orexo submits NDA for sublingual buprenorphine/naloxone product

Sep. 7, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...